Pazopanib is a potent drug approved for Renal Cell Carcinoma and Soft Tissue Sarcoma. It is a tyrosine kinase inhibitor that inhibits tumor growth and blocks angiogenesis. The new study suggests that Pazopanib may lead to a retinal tear and can cause lens detachment. Renal cell carcinoma is the seventh most common type of cancer in men. The recent advances in the systematic medications and innovative surgical treatments have pushed the mortality rates much lower.
The research has shown the utility and effectiveness of Pazopanib, which is tyrosine kinase inhibitor. It inhibits tumor progress and blocks angiogenesis. It targets specific receptors such as VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-A, PDGFR-B, FGFR-1, and FGFR-3. By targeting these specific receptors, Pazopanib acquires more than 90% of clinical success rates. The recent study was published after evaluating ocular effects of…
